Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20224283 | 0.99 | MEN1 (0.33) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL20224498 | 0.97 | PDK2 (0.32) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL20371049 | 0.96 | PDK2 (0.34) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL24039494 | 0.95 | MEN1 (0.33) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL20224507 | 0.94 | MEN1 (0.33) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL20224502 | 0.93 | MEN1 (0.34) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL20224503 | 0.93 | PDK2 (0.38) | MEN1KMT2APOLBPDK2ALDH1A1 | |
| SCHEMBL20224496 | 0.93 | PDK2 (0.36) | MEN1MAPTKMT2APDK2 | |
| SCHEMBL18731771 | 0.92 | MEN1 (0.34) | MEN1MAPTKMT2APOLBDUSP3 | |
| SCHEMBL25004389 | 0.91 | CHEK1 (0.30) | CHEK1WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11183641-B2 | Composition for an organic electronic device and organic electronic device using the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20180159044-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2018-06-07 | — | — | US | disclosed |
| US-20180159044-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11183641-B2 | Composition for an organic electronic device and organic electronic device using the same | ORC3, ZYX, ESR1 | MEN1 1018/4885MAPT 4073/4885KMT2A 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.